Clinical Trial Update: An Extension Study for Patients Previously Treated With ARQ 501 [Phase 1, Phase 2]

View source ↗

Summary

An extension study of ARQ 501 for patients previously treated with the drug has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ARQ 501

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED